Acorda Therapeutics said usage among neurologists and insurers for its new MS drug Ampyra continued to grow in the third quarter. Contrary to management's professed optimism, however, treatment costs ...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 8,440,703 (“the ‘703 patent”) entitled ...

Late last month, a federal court refused to block copies of Acorda’s biggest-selling drug Ampyra leading up to a patent appeal decision. So the New York drugmaker took matters into its own hands.

Acorda Therapeutics is feting the decision by the U.S. Food & Drug Administration (FDA) to approve the marketing of Ampyra (dalfampridine), the first (and only) oral treatment indicated to improve ...

The FDA is updating healthcare professionals about the risk of seizures in patients with multiple sclerosis (MS) who are starting Ampyra (dalfampridine; Acorda Therapeutics). Using information ...

Acorda Therapeutics, Inc. 's ACOR third-quarter 2015 earnings came in at 11 cents per share, below the year-ago earnings of 48 cents per share. The Zacks Consensus Estimate was however pegged at a ...

Third quarter revenues shot up 46.2% to $93.0 million, driven primarily by the milestone payment from Biogen. Revenues exceeded the Zacks Consensus Estimate of $90 million. Product sales consisted ...

Download image SILVER SPRING, Md., Jan. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in ...

The Patent Owner, Acorda Therapeutics, Inc., filed Preliminary Responses against both IPR petitions, raising at least five reasons why institution should be denied. According to Acorda: 1. The IPRs ...

Acorda Therapeutics, Inc.ACOR announced preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for the fourth quarter of 2017 and issued a financial outlook for 2018 at the JP Morgan ...